Figure 3.
Subgroup analyses of the influence of IFN-free DAA therapy on recurrence after curative treatment. Subgroup analyses of the hazard ratio of the influence of IFN-free DAA therapy on HCC recurrence by a time-dependent extended Cox proportional hazards model. HCC: hepatocellular carcinoma, IFN-free DAA: interferon-free direct-acting antiviral therapy